| Drug Name |
Mecasermin |
| Drug ID |
BADD_D01358 |
| Description |
Mecasermin contains recombinant-DNA-engineered human insulin-like growth factor-1 (rhIGF-1)[FDA Label]. IGF-1 consists of 70 amino acids in a single chain with three intramolecular disulfide bridges and a molecular weight of 7649 daltons. The amino acid sequence of the product is identical to that of endogenous human IGF-1. The rhIGF-1 protein is synthesized in bacteria (E. coli) that have been modified by the addition of the gene for human IGF-1. |
| Indications and Usage |
For the long-term treatment of growth failure in pediatric patients with Primary IGFD or with GH gene deletion who have developed neutralizing antibodies to GH. It is not indicated to treat Secondary IGFD resulting from GH deficiency, malnutrition, hypothyroidism or other causes; it is not a substitute for GH therapy. |
| Marketing Status |
Prescription |
| ATC Code |
H01AC03 |
| DrugBank ID |
DB01277
|
| KEGG ID |
D03297
|
| MeSH ID |
C000604197
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
D0F3JT
|
| NDC Product Code |
69443-512; 15054-1040; 69443-510; 49187-0810 |
| Synonyms |
mecasermin | mescamerin recombinant | CEP-151 | Increlex |
